Skye Bioscience Statistics

Total Valuation

Skye Bioscience has a market cap or net worth of $63.52 million. The enterprise value is $4.71 million.

Market Cap	63.52M
Enterprise Value	4.71M

Important Dates

The last earnings date was Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Skye Bioscience has 30.98 million shares outstanding. The number of shares has increased by 201.59% in one year.

Current Share Class	30.98M
Shares Outstanding	30.98M
Shares Change (YoY)	+201.59%
Shares Change (QoQ)	-0.79%
Owned by Insiders (%)	1.57%
Owned by Institutions (%)	46.32%
Float	17.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.07
P/TBV Ratio	1.07
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.85, with a Debt / Equity ratio of 0.01.

Current Ratio	11.85
Quick Ratio	11.14
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-114.08

Financial Efficiency

Return on equity (ROE) is -47.27% and return on invested capital (ROIC) is -31.21%.

Return on Equity (ROE)	-47.27%
Return on Assets (ROA)	-28.04%
Return on Invested Capital (ROIC)	-31.21%
Return on Capital Employed (ROCE)	-60.20%
Revenue Per Employee	n/a
Profits Per Employee	-$2.04M
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Skye Bioscience has paid $10,071 in taxes.

Income Tax	10,071
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -81.89% in the last 52 weeks. The beta is 1.75, so Skye Bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.75
52-Week Price Change	-81.89%
50-Day Moving Average	1.96
200-Day Moving Average	3.65
Relative Strength Index (RSI)	55.35
Average Volume (20 Days)	1,721,397

Short Selling Information

The latest short interest is 3.30 million, so 10.66% of the outstanding shares have been sold short.

Short Interest	3.30M
Short Previous Month	2.67M
Short % of Shares Out	10.66%
Short % of Float	18.65%
Short Ratio (days to cover)	1.80

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-35.80M
Pretax Income	-42.28M
Net Income	-32.65M
EBITDA	-35.35M
EBIT	-35.80M
Earnings Per Share (EPS)	-$0.83

Full Income Statement

Balance Sheet

The company has $59.22 million in cash and $412,111 in debt, giving a net cash position of $58.81 million or $1.90 per share.

Cash & Cash Equivalents	59.22M
Total Debt	412,111
Net Cash	58.81M
Net Cash Per Share	$1.90
Equity (Book Value)	59.25M
Book Value Per Share	1.91
Working Capital	57.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.71 million and capital expenditures -$1.61 million, giving a free cash flow of -$31.32 million.

Operating Cash Flow	-29.71M
Capital Expenditures	-1.61M
Free Cash Flow	-31.32M
FCF Per Share	-$1.01

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Skye Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-201.59%
Shareholder Yield	-201.59%
Earnings Yield	-51.40%
FCF Yield	-49.31%

Analyst Forecast

The average price target for Skye Bioscience is $16.60, which is 709.76% higher than the current price. The consensus rating is "Buy".

Price Target	$16.60
Price Target Difference	709.76%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	29.71%

Stock Forecasts

Stock Splits

The last stock split was on September 8, 2023. It was a reverse split with a ratio of 0.004:1.

Last Split Date	Sep 8, 2023
Split Type	Reverse
Split Ratio	0.004:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	2